Jefferies Raises PT and Estimates on Gilead Sciences (GILD); Stribild (Quad Pill) Approved

Article Stock Quotes (1) Comments (0)

Jefferies maintains a 'Hold' on Gilead Sciences (NASDAQ: GILD) price target of $55.00 (from $53.00).

Analyst, Thomas Wei, said, "The FDA approved GILD's Stribild (quad pill) with a label that was largely in line with expectations. GILD announced Stribild pricing of $28,500/year, which represents a premium to our assumption of $22,263. We are raising our PT to $55 on the basis of Stribild pricing, but we remain cautious on GILD based on valuation."

FY12 EPS estimate raised from $3.78 to $3.79 and FY13 from $4.05 to $4.12.

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $57.19 yesterday, with a 52 week range of $34.45-$58.84.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UBS Survey Shows Signs of Strength for Gilead's (GILD) TAF
• SunPower (SPWR) Not Worth More than $13/Share, Says Goldman
• Cisco (CSCO) PT Raised to $26.50 at Nomura

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change, FDA

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?